Navone NM - Search Results

1

Genome-wide CRISPR screens reveal synthetic lethality of RNASEH2 deficiency and ATR inhibition.

Wang C, Wang G, Feng X, Shepherd P, Zhang J, Tang M, Chen Z, Srivastava M, McLaughlin ME, Navone NM, Hart GT, Chen J. Wang C, et al. Among authors: navone nm. Oncogene. 2019 Apr;38(14):2451-2463. doi: 10.1038/s41388-018-0606-4. Epub 2018 Dec 7. Oncogene. 2019. PMID: 30532030 Free PMC article.

2

Low-density lipoprotein receptor-related protein 5 (LRP5) mediates the prostate cancer-induced formation of new bone.

Li ZG, Yang J, Vazquez ES, Rose D, Vakar-Lopez F, Mathew P, Lopez A, Logothetis CJ, Lin SH, Navone NM. Li ZG, et al. Among authors: navone nm. Oncogene. 2008 Jan 24;27(5):596-603. doi: 10.1038/sj.onc.1210694. Epub 2007 Aug 13. Oncogene. 2008. PMID: 17700537

3

A 45-kDa ErbB3 secreted by prostate cancer cells promotes bone formation.

Lin SH, Cheng CJ, Lee YC, Ye X, Tsai WW, Kim J, Pasqualini R, Arap W, Navone NM, Tu SM, Hu M, Yu-Lee LY, Logothetis CJ. Lin SH, et al. Among authors: navone nm. Oncogene. 2008 Sep 4;27(39):5195-203. doi: 10.1038/onc.2008.156. Epub 2008 May 19. Oncogene. 2008. PMID: 18490922 Free PMC article.

4

Hyperactivated FRS2α-mediated signaling in prostate cancer cells promotes tumor angiogenesis and predicts poor clinical outcome of patients.

Liu J, You P, Chen G, Fu X, Zeng X, Wang C, Huang Y, An L, Wan X, Navone N, Wu CL, McKeehan WL, Zhang Z, Zhong W, Wang F. Liu J, et al. Oncogene. 2016 Apr 7;35(14):1750-9. doi: 10.1038/onc.2015.239. Epub 2015 Jun 22. Oncogene. 2016. PMID: 26096936 Free PMC article.

5

Targeting DNA Damage Response in Prostate Cancer by Inhibiting Androgen Receptor-CDC6-ATR-Chk1 Signaling.

Karanika S, Karantanos T, Li L, Wang J, Park S, Yang G, Zuo X, Song JH, Maity SN, Manyam GC, Broom B, Aparicio AM, Gallick GE, Troncoso P, Corn PG, Navone N, Zhang W, Li S, Thompson TC. Karanika S, et al. Cell Rep. 2017 Feb 21;18(8):1970-1981. doi: 10.1016/j.celrep.2017.01.072. Cell Rep. 2017. PMID: 28228262 Free PMC article.

6

Movember GAP1 PDX project: An international collection of serially transplantable prostate cancer patient-derived xenograft (PDX) models.

Navone NM, van Weerden WM, Vessella RL, Williams ED, Wang Y, Isaacs JT, Nguyen HM, Culig Z, van der Pluijm G, Rentsch CA, Marques RB, de Ridder CMA, Bubendorf L, Thalmann GN, Brennen WN, Santer FR, Moser PL, Shepherd P, Efstathiou E, Xue H, Lin D, Buijs J, Bosse T, Collins A, Maitland N, Buzza M, Kouspou M, Achtman A, Taylor RA, Risbridger G, Corey E. Navone NM, et al. Prostate. 2018 Dec;78(16):1262-1282. doi: 10.1002/pros.23701. Epub 2018 Aug 2. Prostate. 2018. PMID: 30073676

7

The estrogen receptor variants β2 and β5 induce stem cell characteristics and chemotherapy resistance in prostate cancer through activation of hypoxic signaling.

Faria M, Shepherd P, Pan Y, Chatterjee SS, Navone N, Gustafsson JÅ, Strom A. Faria M, et al. Oncotarget. 2018 Nov 20;9(91):36273-36288. doi: 10.18632/oncotarget.26345. eCollection 2018 Nov 20. Oncotarget. 2018. PMID: 30555629 Free PMC article.

8

Oncogenic and osteolytic functions of histone demethylase NO66 in castration-resistant prostate cancer.

Sinha KM, Bagheri-Yarmand R, Lahiri S, Lu Y, Zhang M, Amra S, Rizvi Y, Wan X, Navone N, Ozpolat B, Logothetis C, Gagel RF, Huard J. Sinha KM, et al. Oncogene. 2019 Jun;38(25):5038-5049. doi: 10.1038/s41388-019-0774-x. Epub 2019 Mar 11. Oncogene. 2019. PMID: 30858546

9

The MD Anderson Prostate Cancer Patient-derived Xenograft Series (MDA PCa PDX) Captures the Molecular Landscape of Prostate Cancer and Facilitates Marker-driven Therapy Development.

Palanisamy N, Yang J, Shepherd PDA, Li-Ning-Tapia EM, Labanca E, Manyam GC, Ravoori MK, Kundra V, Araujo JC, Efstathiou E, Pisters LL, Wan X, Wang X, Vazquez ES, Aparicio AM, Carskadon SL, Tomlins SA, Kunju LP, Chinnaiyan AM, Broom BM, Logothetis CJ, Troncoso P, Navone NM. Palanisamy N, et al. Among authors: navone nm. Clin Cancer Res. 2020 Sep 15;26(18):4933-4946. doi: 10.1158/1078-0432.CCR-20-0479. Epub 2020 Jun 23. Clin Cancer Res. 2020. PMID: 32576626 Free PMC article.

10

Enhanced Viability for Ex vivo 3D Hydrogel Cultures of Patient-Derived Xenografts in a Perfused Microfluidic Platform.

Sablatura LK, Bircsak KM, Shepherd P, Queiroz K, Farach-Carson MC, Constantinou PE, Saleh A, Navone N, Harrington DA. Sablatura LK, et al. J Vis Exp. 2020 Dec 5;(166):10.3791/60872. doi: 10.3791/60872. J Vis Exp. 2020. PMID: 33346184 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

150 results

Search Page

Filters